NASDAQ:SLXN Stock Quote
Silexion Therapeutics Corp is a biotechnology company focused on developing innovative therapies to address unmet medical needs in various therapeutic areas
The company specializes in the discovery and advancement of novel drug candidates utilizing its proprietary technologies. With a commitment to improving patient outcomes, Silexion aims to leverage cutting-edge research and development to create targeted treatments that enhance the quality of life for individuals suffering from complex diseases. Through collaboration with academic institutions and industry partners, Silexion strives to bring transformative healthcare solutions to market.
Frequently Asked Questions
How can investors buy shares of Silexion?
Investors can buy shares of Silexion Therapeutics Corp (SLXN) through any brokerage account that offers trading on the Nasdaq stock exchange. By purchasing shares, investors can gain exposure to the company’s potential growth and development in the biopharmaceutical sector.
How does Silexion ensure patient safety during trials?
Silexion Therapeutics Corp prioritizes patient safety during clinical trials by adhering to rigorous ethical standards and regulatory requirements. The company conducts comprehensive preclinical studies, submits detailed trial protocols for approval, and employs independent safety monitoring boards to oversee patient safety throughout the clinical trial process.
How does Silexion handle intellectual property?
Silexion Therapeutics Corp actively manages its intellectual property portfolio to protect its innovations and therapeutic candidates. This includes filing patents for novel compounds and mechanisms of action, ensuring that the company retains exclusive rights to its discoveries and enhances its competitive advantage in the biopharmaceutical market.
Is Silexion Therapeutics Corp publicly traded?
Yes, Silexion Therapeutics Corp is publicly traded on the Nasdaq stock exchange under the ticker symbol SLXN. The company went public as part of a strategy to raise capital for research and development activities, expand its therapeutic pipeline, and enhance shareholder value.
What are the key therapeutic areas Silexion is targeting?
Silexion Therapeutics Corp is primarily targeting key therapeutic areas such as oncology, autoimmune diseases, and other chronic conditions. The company's research aims to identify specific biomarkers and molecular targets that can be addressed through innovative drug solutions, ultimately improving patient outcomes in these areas.
What are the risks associated with investing in Silexion?
Investing in Silexion Therapeutics Corp, like any biotech company, carries risks associated with drug development, including clinical trial failures, regulatory hurdles, and market competition. Additionally, the company's financial performance may be reliant on successful funding and partnerships, making informed investment consideration essential.
What differentiates Silexion from its competitors?
Silexion Therapeutics Corp differentiates itself from competitors through its unique drug discovery platform and focus on specific molecular targets. The company’s dedication to employing advanced technologies and strong scientific partnerships provides a competitive edge in expediting the drug development process and delivering promising new therapies to the market.
What does Silexion Therapeutics Corp do?
Silexion Therapeutics Corp is a biopharmaceutical company focused on developing innovative therapies for treating various chronic diseases. The company's research primarily concentrates on novel drug compounds aimed at addressing significant unmet medical needs in areas such as oncology and autoimmune disorders. Silexion is dedicated to advancing its therapeutic pipeline through rigorous clinical testing and a commitment to scientific excellence.
What is Silexion's approach to research and development?
Silexion's approach to research and development focuses on a combination of cutting-edge technology and novel scientific insights. The company integrates computational biology, high-throughput screening, and preclinical modeling to discover and develop new drug candidates, aiming to create safe and effective treatments for patients.
What is Silexion's main focus in drug development?
Silexion's main focus in drug development is on creating small-molecule therapeutics that target specific cellular pathways implicated in various diseases, particularly in oncology and immunology. The company employs an extensive research approach that combines computational drug design with empirical testing to create effective and targeted therapies with minimal side effects.
What is the company's mission statement?
Silexion Therapeutics Corp's mission statement is to innovate and deliver transformative therapies that significantly improve the quality of life for patients with chronic and serious diseases. The company strives for excellence in science and ethical practice while maintaining a commitment to patient-centered care.
What is the ticker symbol for Silexion Therapeutics Corp?
The ticker symbol for Silexion Therapeutics Corp is SLXN, which is used to identify the company's ordinary shares on the Nasdaq stock exchange. Investors can track the performance of SLXN to gauge market interest and the company's financial status.
What partnerships does Silexion have?
Silexion Therapeutics Corp has established strategic partnerships with leading academic institutions and pharmaceutical companies to enhance its drug development efforts. These collaborations facilitate access to additional resources, expertise, and technologies, thereby accelerating the development of its therapeutic candidates.
What regulatory approvals has Silexion obtained?
As of now, Silexion Therapeutics Corp has obtained several regulatory approvals for its investigational new drugs (INDs) from the U.S. Food and Drug Administration (FDA). These approvals enable the company to initiate clinical trials and test its therapies' safety and effectiveness in human subjects.
What stage are Silexion's clinical trials in?
Silexion Therapeutics Corp has multiple drug candidates at various stages of clinical trials, including Phase 1 and Phase 2. These trials are critical for evaluating the safety and effectiveness of their therapeutics before moving to broader Phase 3 studies, which would determine the drugs' viability for market approval.
What upcoming milestones are important for Silexion?
Upcoming milestones for Silexion Therapeutics Corp include the completion of ongoing clinical trials, announcements of trial results, and potential new drug applications (NDAs) with regulatory agencies. These milestones are critical indicators of the company’s progress and ability to bring new therapeutics to market.
When was Silexion Therapeutics Corp founded?
Silexion Therapeutics Corp was founded in 2021 by a team of experienced scientists and entrepreneurs in the pharmaceutical industry. The company was established with the vision of transforming the treatment landscape for patients suffering from difficult-to-treat conditions by leveraging cutting-edge research and technology in drug development.
Where is Silexion Therapeutics Corp headquartered?
Silexion Therapeutics Corp is headquartered in San Francisco, California, which is known for being a vibrant hub for biotech and pharmaceutical innovation. This strategic location allows the company to collaborate with leading research institutions and access cutting-edge technologies that support its drug development initiatives.
Who are the key executives at Silexion Therapeutics Corp?
Silexion Therapeutics Corp is led by a team of seasoned executives with extensive experience in pharmaceutical development and biotechnology. The team's expertise encompasses areas such as clinical research, regulatory affairs, and commercial strategy, positioning the company to navigate the complexities of bringing new therapies to market.
What is the current price of Silexion Therapeutics Corp - Ordinary Shares?
The current price of Silexion Therapeutics Corp - Ordinary Shares is 0.9920
When was Silexion Therapeutics Corp - Ordinary Shares last traded?
The last trade of Silexion Therapeutics Corp - Ordinary Shares was at 4:00 pm EDT on April 2nd, 2025